Patents Assigned to Vanda Pharmaceuticals, Inc.
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120059035
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: March 8, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120058201
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: March 8, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE
    Publication number: 20120053207
    Abstract: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
    Type: Application
    Filed: May 15, 2010
    Publication date: March 1, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120035215
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: February 9, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE
    Publication number: 20120027871
    Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: February 2, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Ruthenium (II) catalysts for use in stereoselective cyclopropanations
    Patent number: 8097738
    Abstract: Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N?-bis(3,5-di-t-butyl-salicylidene) and RuCl2(p-cymene)]2.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: January 17, 2012
    Assignee: VANDA Pharmaceuticals Inc.
    Inventors: David E. Pereira, Wade Aumiller, Raymond Dagger
  • Ruthenium(II) catalysts for use in stereoselective cyclopropanations
    Patent number: 7754902
    Abstract: Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N?-bis(3,5-di-t-butyl-salicylidene) and RuCl2(p-cymene)]2.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: July 13, 2010
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: David E. Pereira, Wade Aumiller, Raymond Dagger
  • Method of Improving Wakefulness
    Publication number: 20080280954
    Abstract: The present invention relates to the use of certain imidazolylalkyl-pyridines as wakefulness compounds.
    Type: Application
    Filed: July 26, 2006
    Publication date: November 13, 2008
    Applicant: VANDA PHARMACEUTICALS, INC
    Inventors: Christian N. Lavedan, Mihael H. Polymeropoulos